Marker Therapeutics, Inc. (MRKR)

NCM – Real vaqt narxi. Valyuta: USD

1.31

+0.01 (0.38%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.32

+0.00 (0.38%)

Bozordan keyin: Jun 26, 2026, 4:49 PM EDT

20.05.2026

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

18.03.2026

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.

18.03.2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

18.02.2026

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event: Oppenheimer 36 th Annual Healthcare Life Sciences Conference Date: Wednesday, February 25, 2026 Time: 8:00 – 8:30 a.m.

21.01.2026

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.

07.01.2026

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.

07.01.2026

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Videolar

No Data

There is no data to display

Press-relizlar

18.03.2026

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses

05.01.2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study

14.11.2025

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma

05.11.2025

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025.

Marker Therapeutics, Inc. (MRKR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Marker Therapeutics, Inc. (MRKR)

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Videolar

No Data

Press-relizlar

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Videolar

No Data

Press-relizlar

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Search stocks

Marker Therapeutics, Inc. (MRKR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Marker Therapeutics, Inc. (MRKR)

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Videolar

No Data

Press-relizlar

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?

MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know

MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Videolar

No Data

Press-relizlar

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors